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Granulosa cell tumors (GCTs) of the testis are rare sex cord-stromal tumors that are present in both juvenile and adult subtypes.
While most adult GCTs are benign, those that present with distant metastases manifest a grave prognosis. Treatments for aggressive
GCTs are not well established. Options that have been employed in previous cases include retroperitoneal lymph node dissection
(RPLND), radiation, chemotherapy, or a combination thereof. We describe the case of a 57-year-old man who presented with a
painless left testicular mass and painful gynecomastia. Serum tumor markers (alpha fetoprotein, human chorionic gonadotropin,
and lactate dehydrogenase) and computed tomography of the chest and abdomen were negative.The patient underwent left radical
orchiectomy. Immunohistochemical staining was consistent with a testicular GCT. He underwent a left-template laparoscopic
RPLND which revealed 2/19 positive lymph nodes. Final pathological stage was IIA. He remains free of disease 32 months after
surgery.
1. Introduction
Granulosa cell tumors (GCTs) of the testis are sex cord-
stromal tumors that are represented by both juvenile and
adult subtypes. Juvenile testicular GCTs account for only 1–
4%of prepubertal testicular tumors but are themost common
testicular stromal tumors in boys < 6 months of age [1].
Compared to the juvenile type, adult testicular GCTs are
extremely rare. Stromal testicular tumors (including Sertoli
and Leydig cell tumors) account for only 4% of all testicular
tumors, and GCTs are the rarest of testicular stromal tumors
[2]. A literature review by Schubert et al. in 2014 found only
43 cases of adult GCT described to date, and six additional
reports have been made since [3–7]. Most cases of adult GCT
present as a painless testicular mass. Gynecomastia may be
present in approximately 17% of cases and is attributable to
the tumor’s synthesis of estradiol [8–10]. While most adult
GCTs are benign, those that present with distant metastases
confer a poor prognosis. Consensus on the optimal approach
to such cases is lacking. Previous authors have proposed
retroperitoneal lymph node dissection (RPLND), radiation,
chemotherapy, or a combination thereof.
2. Case Presentation
A 57-year-old male presented for evaluation of a painless left
testicular mass. He discovered the mass on self-exam. The
mass had been slowly increasing in size over the previous
three months. He also noted painful bilateral gynecomastia.
Review of systemswas negative for fevers, chills, night sweats,
nausea, vomiting, fatigue, anorexia, and shortness of breath.
He noticed no change in libido or erectile function. He was
not aware of any palpable lymph nodes. His past medical
history otherwise included atrial fibrillation and obstructive
sleep apnea. He had no history of abdominal or pelvic
surgery. He denied history of cryptorchidism. Family history
was notable for breast and lung cancer, but no urologic
malignancy.
On exam, the patient had a painless nodular mass in
his left testis and a left-sided hydrocele. The right testis was
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Figure 1: Testicular ultrasound. Longitudinal examination of the left
testis demonstrates a heterogeneousmass, which has nearly replaced
all normal testicular parenchyma. A small reactive hydrocele is
present.
unremarkable. His epididymideswere normal bilaterally with
no masses, tenderness, or induration. He had no palpable
inguinal lymphnodes.His abdominal exam and the reminder
of his genital exam were normal. Gynecomastia was present,
and the breast tissue was tender to palpation.
Serum blood counts and chemistries were normal. Alpha
fetoprotein (AFP), human chorionic gonadotropin (hCG),
and lactate dehydrogenase (LDH) were normal (0.8 ng/mL,
<2mIU/mL, and 186U/L, resp.). A scrotal ultrasound showed
a 4.5 cm hyperemic left testicular mass infiltrating and essen-
tially replacing the left testicle, as well as a reactive left
hydrocele (Figure 1). Computerized tomography (CT) scan
of the chest, abdomen, and pelvis showed no retroperitoneal
or pelvic lymphadenopathy and no evidence of metastatic
disease.
The patient underwent left radical inguinal orchiectomy
without complications. The left testis mass was 4.7 cm ×
2.8 cm × 2.3 cm on gross examination. Histological examina-
tion revealed abundant neoplastic cells with scant cytoplasm
and round-to-oval nuclei with longitudinal grooves. They
infiltrated through the interstitium as nests, cords, and single
cells, with focal rosetting, reminiscent of Call-Exner bodies.
The immunohistochemical profile (coexpression of vimentin,
inhibin, scattered cytokeratin, and CD56) was consistent
with testicular GCT (Figure 2). Neuroendocrine tumor and
malignant melanoma were excluded (negative chromogranin
and synaptophysin; negative HMB-45 and Melan-A). Tumor
invaded into the adnexa and lymphovascular space.
The patient was counseled regarding the paucity of litera-
ture related to the management of GCT. Treatment options
including RPLND, chemotherapy, and active surveillance
were discussed. The patient elected to undergo left-template
laparoscopic RPLND. Twelve interaortocaval lymph nodes
and 7 periaortic lymph nodes were removed. Microscopic
examination revealed 2/12 interaortocaval nodes with his-
tology consistent with GCT metastases (both <2 cm in size)
(Figure 3).Thepatient’s final stagewas IIA (pT2/N1/M0)GCT
of the testis.
Four months after his initial presentation, the patient
complained of fatigue and decreased muscle mass. He was
found to have decreased serum free and total testosterone
(26.5 pg/mL and 234 ng/dL, resp.), increased follicle-stimula-
ting hormone (FSH) (53.6mIU/mL), and increased luteiniz-
ing hormone (LH) (13.3mIU/mL). Estradiol (18 pg/mL),
thyroid-stimulating hormone (2.12mIU/L), and free thyrox-
ine (T4) (1.3 ng/dL) were normal. These results were consis-
tent with primary hypogonadism. He declined testosterone
replacement therapy. In the months following RPLND, he
complained of worsening bilateral painful gynecomastia.
He underwent bilateral mastectomy. Thirteen months after
initial presentation, his free and total testosterone levels
had normalized (42.8 pg/mL and 266 ng/dL, resp.) with
persistently elevated FSH and LH, indicative of compensated
primary hypogonadism. Blood work drawn at 26 months
showed stable levels of testosterone, FSH, and LH. Surveil-
lance CT scans of his chest, abdomen, and pelvis obtained
every 6 months following RPLND have been negative for
recurrence. His most recent follow-up was 32 months after
initial presentation.
3. Discussion
Approximately 25% of adult testicular GCTs display mali-
gnant features, thus necessitating careful clinical and histo-
pathologic investigations to evaluate metastasis and metasta-
tic potential. However, due to the scant number of cases,
factors predictive of malignancy have not yet been clearly
defined. In 2011, Hanson and Ambaye reviewed all prior
cases of adult GCTs (𝑛 = 29, with 6 being malignant) [11].
On univariate analysis, tumor size greater than 5.0 cmwas the
only feature statistically associated with malignancy; patient
age, mitotic activity, tumor necrosis, and the presence of
gynecomastia did not predict benign versusmalignant behav-
ior.
The prognosis for patients with malignant GCTs is vari-
able and not well-defined, again owing to its infrequency.
Following a review of the literature, Hammerich et al. found
that patients with distant or multiple metastases (𝑛 = 3)
progressed quickly and had limited survival (as little as
five months following diagnosis). Conversely, patients with
metastasis to retroperitoneal lymph nodes only (𝑛 = 2)
tended to have a longer survival period (one patient was alive
with disease at 14 months following RPLND and chemother-
apy; the second patient was without evidence of disease at
168months followingRPLNDand radiation) [12].Thepatient
presented herein is presently without evidence of disease
despite lymph node positivity discovered on RPLND. Clearly,
larger numbers of patients with longer follow-up periods are
needed to providemore definitive prognoses for patients with
metastatic spread.
To date, there are no well-established treatment guide-
lines for the malignant variants of adult testicular GCTs.
The rarity of the condition precludes definitive management
algorithms. A review of reported cases by Hammerich et al.
suggests that various options may be viable and that a com-
bination of treatment modalities (RPLND, chemotherapy,
and radiation)may prove to be advantageous. Chemotherapy
regimens have included bleomycin, etoposide, and cisplatin,
or doxorubicin and cisplatin. In the absence of metastatic
disease on cross-sectional imaging, active surveillance is also
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Figure 2: Testicular granulosa cell tumor histology. Sections of the testis show a nested neoplasm composed of undifferentiated to poorly
differentiated cells infiltrating through the interstitium.The cells have scant cytoplasm and round-to-oval nuclei with occasional longitudinal
nuclear groves.There is a suggestion of rosette formation in some areas, which could representCall-Exner bodies.Mitotic figures are identified.
The overall morphology is consistent with a granulosa cell tumor, adult type (a). Immunohistochemistry shows that the tumor cells are
diffusely positive for inhibin (b).
Figure 3: Metastatic granulosa cell tumor in an interaortocaval
lymph node. A tumor nest is present in the subcapsular space of an
interaortocaval lymph node. The neoplastic cells have scant cyto-
plasm and oval nuclei with conspicuous longitudinal groves, con-
sistent with the patient’s known primary testicular granulosa cell
tumor.
a reasonable option. It has previously been suggested, based
on experience with sex cord-stromal tumors (not specifically
GCTs), that RPLND may be beneficial in stage 1 disease, but
less effective in N1 cases [2]. The patient in the present case
has been counseled regarding the possible benefit of adjuvant
chemotherapy but has elected for close active surveillance at
this time.
4. Conclusion
The experience presented herein suggests that primary
RPLNDwith or without neoadjuvant or adjuvant chemother-
apy may be a viable option in select patients with testicular
GCT. Patients may experience the sequelae of changes in
testicular endocrine function and should bemonitored based
on symptomatology.
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